Akula Concentrate Zagro Australia Pty Ltd

Chemwatch: **5358-33**Version No: **3.1.1.1**

Safety Data Sheet according to WHS and ADG requirements

Chemwatch Hazard Alert Code: 3

Issue Date: **01/11/2019**Print Date: **24/02/2021**L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	Akula Concentrate
Chemical Name	Not Applicable
Synonyms	Not Available
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Jetting fluid.
--------------------------	----------------

Details of the supplier of the safety data sheet

Registered company name	Zagro Australia Pty Ltd	
Address	7 Koojan Avenue South Guildford, Perth WA 6055 Australia	
Telephone	+61 8 9321 2888	
Fax	Not Available	
Website	Not Available	
Email	askzagro@zagro.com	

Emergency telephone number

Association / Organisation	Technical Support	
Emergency telephone numbers	+61 8 9321 2888 (Mon - Fri 8am - 5pm WST)	
Other emergency telephone numbers	Not Available	

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	S7
Classification [1]	Acute Toxicity (Oral) Category 4, Reproductive Toxicity Category 1B, Lactation Effects, Acute Aquatic Hazard Category 3
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

Label elements

Hazard pictogram(s)





Signal word

Danger

Hazard statement(s)

H302

Harmful if swallowed.

Issue Date: 01/11/2019 Print Date: 24/02/2021

H360D	May damage the unborn child.
H362	May cause harm to breast-fed children.
H402	Harmful to aquatic life.

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P260	Do not breathe mist/vapours/spray.
P263	Avoid contact during pregnancy and while nursing.
P280	Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/
P270	Do not eat, drink or smoke when using this product.
P273	Avoid release to the environment.

Precautionary statement(s) Response

P308+P313	P308+P313 IF exposed or concerned: Get medical advice/attention.	
P301+P312 IF SWALLOWED: Call a POISON CENTER/doctor/ if you feel unwell		
P330	Rinse mouth.	

Precautionary statement(s) Storage

P405	Store locked up.
------	------------------

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
70288-86-7	1.6	ivermectin
Not Available	balance	Ingredients determined not to be hazardous

SECTION 4 First aid measures

Description of first aid measures		
Eye Contact	If this product comes in contact with the eyes: Nash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.	
Skin Contact	If skin or hair contact occurs: Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.	
Inhalation	 If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary. 	
Ingestion	 IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. For advice, contact a Poisons Information Centre or a doctor. Urgent hospital treatment is likely to be needed. In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition. If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist. If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS. Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or 	

 Chemwatch: 5358-33
 Page 3 of 11
 Issue Date: 01/11/2019

 Version No: 3.1.1.1
 Akula Concentrate
 Print Date: 24/02/2021

unless instructed otherwise:

• INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.

NOTE: Wear a protective glove when inducing vomiting by mechanical means.

Indication of any immediate medical attention and special treatment needed

As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).

For poisons (where specific treatment regime is absent):

BASIC TREATMENT

- Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 L/min.
- Monitor and treat, where necessary, for pulmonary oedema.
- Monitor and treat, where necessary, for shock.
- Anticipate seizures.
- ▶ DO NOT use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

ADVANCED TREATMENT

ADVANCED TREATMENT

- Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
- Positive-pressure ventilation using a bag-valve mask might be of use.
- Monitor and treat, where necessary, for arrhythmias.
- Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- Treat seizures with diazepam.
- ▶ Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.

EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

Toxicity following accidental ingestion of ivermectin can be minimised by inducing vomiting within one half-hour of exposure. Since ivermectin is believed to bind to glutamate-gated chloride ion channels, it is probably wise to avoid drugs that also interact with other ligand-gated chloride channels including those that enhance GABA activity in patients with potentially toxic ivermectin exposure. [Mercke, Sharpe and Dohme]

SECTION 5 Firefighting measures

Extinguishing media

- ▶ There is no restriction on the type of extinguisher which may be used.
- Use extinguishing media suitable for surrounding area.

Special hazards arising from the substrate or mixture

Fire Incompatibility None known.

Advice for firefighters

- Alert Fire Brigade and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves in the event of a fire.
- Prevent, by any means available, spillage from entering drains or water courses.
- Use fire fighting procedures suitable for surrounding area.
- DO NOT approach containers suspected to be hot.
- Cool fire exposed containers with water spray from a protected location.
- If safe to do so, remove containers from path of fire.
- Equipment should be thoroughly decontaminated after use.

Fire/Explosion Hazard

Non combustible.Not considered a significant fire risk, however containers may burn.

May emit poisonous fumes.

HAZCHEM

Fire Fighting

Not Applicable

SECTION 6 Accidental release measures

Issue Date: **01/11/2019**Print Date: **24/02/2021**

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

memora and manor and occurrence of the control of t		
Minor Spills	 Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite. Wipe up. Place in a suitable, labelled container for waste disposal. 	
Major Spills	Moderate hazard. Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. Stop leak if safe to do so. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Neutralise/decontaminate residue (see Section 13 for specific agent). Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. If contamination of drains or waterways occurs, advise emergency services.	

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling Avoid all personal contact, including inhalation. ▶ Wear protective clothing when risk of exposure occurs. ▶ Use in a well-ventilated area. ▶ Prevent concentration in hollows and sumps. ▶ DO NOT enter confined spaces until atmosphere has been checked ▶ DO NOT allow material to contact humans, exposed food or food utensils. Avoid contact with incompatible materials. ▶ When handling, **DO NOT** eat, drink or smoke. Safe handling Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. ▶ Work clothes should be laundered separately. Launder contaminated clothing before re-use. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained. ▶ Store in original containers. Keep containers securely sealed. Store in a cool, dry, well-ventilated area. Other information Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. ▶ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	 Polyethylene or polypropylene container. Packing as recommended by manufacturer. Check all containers are clearly labelled and free from leaks.
Storage incompatibility	Avoid contamination of water, foodstuffs, feed or seed.

SECTION 8 Exposure controls / personal protection

Control parameters

Issue Date: 01/11/2019 Print Date: 24/02/2021

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Not Available

Emergency Limits

Ingredient	Material name	TEEL-1	TEEL-2	TEEL-3
Akula Concentrate	Not Available	Not Available	Not Available	Not Available

Ingredient	Original IDLH	Revised IDLH
ivermectin	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit	
ivermectin	Е	≤ 0.01 mg/m³	
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.		

MATERIAL DATA

Exposure controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.

The basic types of engineering controls are:

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure.

General exhaust is adequate under normal operating conditions. If risk of overexposure exists, wear SAA approved respirator. Correct fit is essential to obtain adequate protection. Provide adequate ventilation in warehouse or closed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:

0.25-0.5 m/s solvent, vapours, degreasing etc., evaporating from tank (in still air) (50-100 f/min) aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, 0.5-1 m/swelding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active (100-200 f/min.) generation) direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas 1-2.5 m/s

discharge (active generation into zone of rapid air motion) grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).

2.5-10 m/s (500-2000 f/min.)

(200-500 f/min)

Air Speed:

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood - local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min.) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Appropriate engineering controls

Issue Date: **01/11/2019**Print Date: **24/02/2021**

Personal protection









· crocman protoculor

- ► Safety glasses with side shields
- Chemical goggles.
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

Skin protection

Eye and face protection

See Hand protection below

- ▶ Wear chemical protective gloves, e.g. PVC.
- Wear safety footwear or safety gumboots, e.g. Rubber

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- frequency and duration of contact,
- · chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- · When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.

Hands/feet protection

Contaminated gloves should be replaced.

- As defined in ASTM F-739-96 in any application, gloves are rated as: $\cdot \qquad \text{Excellent when breakthrough time} > 480 \; \text{min}$
- Good when breakthrough time > 20 min
- Fair when breakthrough time < 20 min
- · Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task. Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

- Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.
- · Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Body protection

See Other protection below

Other protection

- Overalls.P.V.C apron.
- Barrier cream.
- Skin cleansing cream.
- ► Eye wash unit.

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance

Clear liquid; mixes with water.

Page **7** of **11**

Akula Concentrate

Issue Date: **01/11/2019** Print Date: **24/02/2021**

Physical state	Liquid	Relative density (Water = 1)	~1
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable
pH (as supplied)	6-7.5	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Applicable	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	 Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. The maximum attainable concentration of 5.11 mg/l ivermectin produced transient irritation of mucous membranes in rats but no deaths or other signs of toxicity after one hour exposure. An acute inhalation study showed a low order of toxicity in animals but this was attributed to the larger particle size of the sample used in the study.
Ingestion	Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
Skin Contact	Skin contact is not thought to produce harmful health effects (as classified under EC Directives using animal models). Systemic harm, however, has been identified following exposure of animals by at least one other route and the material may still produce health damage following entry through wounds, lesions or abrasions. Good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).
Chronic	There is sufficient evidence to provide a strong presumption that human exposure to the material may result in developmental toxicity, generally on the basis of: - clear results in appropriate animal studies where effects have been observed in the absence of marked maternal toxicity, or at

Chemwatch: 5358-33 Version No: 3.1.1.1

Page 8 of 11 Akula Concentrate

Issue Date: 01/11/2019 Print Date: 24/02/2021

around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects.

Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

May cause harm to breastfed babies.

There is some evidence to provide a presumption that human exposure to the material may result in impaired fertility on the basis of: some evidence in animal studies of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects but which is not a secondary non-specific consequence of other toxic effects.

Akula Concentrate	TOXICITY Not Available	IRRITATION Not Available	
ivermectin	TOXICITY Dermal (rabbit) LD50: 406 mg/kg ^[2] Oral(Rat) LD50; 2 mg/kg ^[2]	IRRITATION Eye (rabbit): slight ** Skin (rabbit): non-irritating **	
Legend:	Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances		

No significant acute toxicological data identified in literature search.

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production.

The material may produce respiratory tract irritation. Symptoms of pulmonary irritation may include coughing, wheezing, larvngitis, shortness of breath, headache, nausea, and a burning sensation.

Unlike most organs, the lung can respond to a chemical insult or a chemical agent, by first removing or neutralising the irritant and then repairing the damage (inflammation of the lungs may be a consequence).

The repair process (which initially developed to protect mammalian lungs from foreign matter and antigens) may, however, cause further damage to the lungs (fibrosis for example) when activated by hazardous chemicals. Often, this results in an impairment of gas exchange, the primary function of the lungs. Therefore prolonged exposure to respiratory irritants may cause sustained breathing difficulties.

IVERMECTIN

For ivermectin:

Therapeutic doses of 0.2 mg/kg do not produce signs of toxicity in a variety of species including humans.

There were no gross or histological changes seen in dogs treated with ivermectin for 3 months (no-observed-adverse-effect-level (NOAEL) = 0.5 mg/kg/day) or in monkeys treated for 2 weeks (NOAEL = 1.2 mg/kg/day).

Changes in the spleen, bone marrow and kidneys were reported in rats treated for 3 months (NOAEL = 0.4 mg/kg/day). Ivermectin produced developmental toxicity in mice, rats and rabbits at or near dosage levels that were maternally toxic (NOAEL = 0.1 mg/kg/day in mice, the most sensitive species). Neonatal rats are about 20 times more susceptible to ivermectin than adult rats because the blood brain barrier is not fully developed until after birth. There has been no evidence of teratogenicity in controlled studies in pregnant cattle, swine and dogs at up to three times the clinical dose nor has breeding performance been affected in various species.

Reproductive effects: Rats given 0.40 mg/kg/day of ivermectin had increased stillbirths, decreased pup viability, decreased lactation, and decreased pup weights. These data suggest that ivermectin may have the potential to cause reproductive effects at high enough doses.

Teratogenic effects: Ivermectin produced cleft palate in the offspring of treated mice and rabbits, but only at doses that were also toxic to the mothers. There were no birth defects in the offspring of rats given up to 1 mg/kg/day. Ivermectin is unlikely to cause teratogenic effects except at doses toxic to the mother.

The targeted clinical dosage of 0.15-0.2 mg/kg and doses in the range of 3 to 12 mg are given according to body weight. Higher dosages (0.4 mg/kg) have been given to patients with lymphatic filariasis. For treatment of onchocerciasis caused by Onchcerca volvulus, a leading cause of river blindness in tropical areas), the drug is given only once every six or

twelve months. Ivermectin is metabolised in the liver and excreted almost exclusively in the faeces over a period of twelve days. The plasma half-life in man is about 10-12 hours for ivermectin and 3 days for its metabolites. Side-effects are not considered to be due to the toxicity of ivermectin as such, but are attributed to hypersensitivity reactions resulting from the death of the microfilariae. In cases of accidental overdose with ivermectin, there have been no fatalities reported; however symptoms resemble those in animal studies

Mutagenic effects: Ivermectin does not appear to be mutagenic. Mutagenicity tests in live rats and mice were negative.

Chemwatch: **5358-33**Version No: **3.1.1.1**

Page 9 of 11

Akula Concentrate

Issue Date: **01/11/2019**Print Date: **24/02/2021**

Ivermectin was shown to be nonmutagenic in the Ames test.

Carcinogenic effects: Ivermectin is not carcinogenic in rats or mice. The rats were fed dietary doses of up to 2 mg/kg/day for 24 months, and the mice were up to 8 mg/kg/day for 22 months. These represent the maximum tolerated doses

Oral (Rat) LD50: 2-3 mg/kg ** ADI: 0.8 mg/day ** * [Mercke] ** [Mercke, Sharpe and Dohme]

Acute Toxicity	~	Carcinogenicity	×
Skin Irritation/Corrosion	×	Reproductivity	✓
Serious Eye Damage/Irritation	×	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

Legend:

X - Data either not available or does not fill the criteria for classification

✓ – Data available to make classification

SECTION 12 Ecological information

Toxicity

	Endpoint	Test Duration (hr) Species			Value	Source	
Akula Concentrate	Not Available	Not Available Not Available			Not Available	Not Available	
	Endpoint	Test Duration (hr)	Spec	cies	Value		Source
	LC50	96	Fish		-0.0025-0.0036mg/L		4
	EC50	48	Crustacea -0.00049-0.0		0.00072mg/L	4	
ivermectin	EC50	72	Alga	e or other aquatic plants	>4-mg/L		4
	BCF	144	Not /	Available	0.0069-m	g/L	4
	EC80	504	Not /	Not Available -0.001-0.061mg/L		61mg/L	4
	NOEC	504	Crus	tacea	0.000000	0003-mg/L	4

Legend:

Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

Harmful to aquatic organisms.

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
	No Data available for all ingredients	No Data available for all ingredients

Bioaccumulative potential

Ingredient	Bioaccumulation	
	No Data available for all ingredients	

Mobility in soil

Ingredient	Mobility	
	No Data available for all ingredients	

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal

- ▶ Containers may still present a chemical hazard/ danger when empty.
- Return to supplier for reuse/ recycling if possible. Otherwise:

Issue Date: **01/11/2019**Print Date: **24/02/2021**

- If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product.
- DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- ► Recycle wherever possible.
- Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or incineration in a licensed apparatus (after admixture with suitable combustible material).
- ▶ Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

SECTION 14 Transport information

Labels Required

·	
Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group	
ivermectin	Not Available	

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
ivermectin	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

ivermectin is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4 Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5 Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 7

National Inventory Status

National Inventory	Status	
Australia - AIIC / Australia Non-Industrial Use	No (ivermectin)	
Canada - DSL	Yes	
Canada - NDSL	No (ivermectin)	
China - IECSC	No (ivermectin)	
Europe - EINEC / ELINCS / NLP	Yes	
Japan - ENCS	No (ivermectin)	
Korea - KECI	No (ivermectin)	
New Zealand - NZIoC	Yes	
Philippines - PICCS	No (ivermectin)	
USA - TSCA	No (ivermectin)	

Chemwatch: 5358-33 Page 11 of 11 Issue Date: 01/11/2019 Version No: 3.1.1.1 Print Date: 24/02/2021

Akula Concentrate

National Inventory	Status		
Taiwan - TCSI	Yes		
Mexico - INSQ	No (ivermectin)		
Vietnam - NCI	No (ivermectin)		
Russia - ARIPS	No (ivermectin)		
	Yes = All CAS declared ingredients are on the inventory		
Legend:	No = One or more of the CAS listed ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)		

SECTION 16 Other information

Revision Date	01/11/2019
Initial Date	03/07/2019

SDS Version Summary

Version	Issue Date	Sections Updated
3.1.1.1	01/11/2019	One-off system update. NOTE: This may or may not change the GHS classification

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit。

IDLH: Immediately Dangerous to Life or Health Concentrations

OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value **BCF**: BioConcentration Factors BEI: Biological Exposure Index

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.